Taiwan Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape

1.1 List of Figures
1.2 List of Tables

2.1 Executive Summary
2.2 Key Highlights - Facts about the Taiwan Healthcare Market
2.3 Key Highlights: Healthcare Startups in Taiwan
2.4 Key Events: Taiwan Pharmaceutical News 2016-22
2.5 Key Events: Taiwan Pharmaceutical Market
2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2021-22
2.7 Key Events: Mergers and Acquisitions
2.8 Country Profile, Taiwan, 2021

3.1 Pharmaceutical Market - Overview
3.2 Pharmaceutical Market - Exports
3.3 Pharmaceutical Market - Imports
3.4 Pharmaceutical Market - Supply Channels, Taiwan
3.5 Pharmaceutical Market - Market Segments
3.6 Pharmaceutical Market - Market Segment: Generic Drugs, Taiwan
3.7 Pharmaceutical Market - Market Segment: Biologics and Biosimilars, Taiwan
3.8 Pharmaceutical Market - Market Segments, Over-the-Counter Medicines, Taiwan
3.9 COVID-19 Epidemiology, Taiwan
3.10 COVID-19 Impact and Developments in the Healthcare Market, Taiwan
3.11 COVID-19 Clinical Trials Landscape, Taiwan
3.12 Pharmaceutical Market - Major Players

4.1 Medical Device Market - Overview
4.2 Medical Device Market - Major Segments
4.3 Medical Device Market - Hospital Supplies Market
4.4 Medical Device Market - Orthopedic Devices Market
4.5 Medical Device Market - Nephrology and Urology Devices Market
4.6 Medical Device Market - Cardiovascular Devices Market
4.7 Medical Device Market - Diabetes Care Devices Market
4.8 Medical Devices Market - Diagnostic Market
4.9 Medical Devices Market - Major Players

5.1 Drivers
5.2 Barriers

6.1 Deal Analysis: Pharmaceutical Market, Taiwan, 2019-22
6.2 Deal Analysis: Medical Device Market, Taiwan, 2019-22

7.1 HealthTech Landscape, Taiwan
7.2 HealthTech Deals Landscape, Taiwan
7.3 Key HealthTech Deals, Taiwan
7.4 Adoption of Technology in Healthcare, Taiwan
7.5 Digital Statistics, Taiwan
7.5 Digital Healthcare Regulations, Taiwan
7.6 Digital Health- Benefits and Risks, Taiwan

8.1 Overview of Healthcare System, Taiwan
8.2 Reimbursement Landscape, Taiwan
8.3 Overview of Insurance Providers, Public Insurance, Taiwan
8.4 Overview of Insurance Providers, Private Insurance, Taiwan
8.5 Healthcare Spending and Prescription Drug Price Trend, Taiwan
8.6 Pricing Policies, Taiwan
8.7 Market Access: Key Events Timeline, Taiwan, 2010-21
8.8 Regulatory Landscape, Taiwan
8.8.1 Marketing Authorization for Pharmaceutical Products, Taiwan
8.8.2 Marketing Authorization for Medical Devices, Taiwan
8.8.3 Pharmaceutical and Medical Device Establishment Regulations, Taiwan
8.8.4 Intellectual Property Rights, Patent, Taiwan
8.8.5 Intellectual Property Rights, Trademark, Taiwan
8.8.6 Clinical Trial Regulation Process, Taiwan
8.8.7 Pharmaceutical Clinical Trials Landscape, Taiwan
8.8.8 Medical Device Clinical Trials Landscape, Taiwan
8.8.9 Pharmaceutical Import and Export, Taiwan
8.8.10 Pharmaceutical Advertising Regulations, Taiwan
8.8.11 Pharmacy Regulations, Taiwan
8.8.12 Labeling and Packaging Regulations, Taiwan

9.1 Healthcare Policy Highlights, Taiwan
9.2 Healthcare Facilities, Taiwan
9.3 Life Expectancy and Immunization Rate, Taiwan
9.4 Environmental Health, Taiwan
9.5 Healthcare Personnel, Taiwan
9.6 Disease Burden, Taiwan
9.7 Healthcare Expenditure, Taiwan
9.8 Healthcare Spending Components and Pharmaceutical Spending, Taiwan

13.1 Research Methodology
13.1.1 Coverage
13.1.2 Secondary Research
13.1.3 Forecasts
13.2 Bibliography
13.3 About the Publisher
13.4 Contact the Publisher
13.5 Disclaimer

Table 1: Role of government agencies working against counterfeit medicines, Taiwan, 2022
Table 2: COVID-19 indicators, global and Taiwan, 2022
Table 3: COVID-19-related travel restrictions, Taiwan, 2020-22
Table 4: Authorized COVID-19 vaccines, Taiwan, 2020-22
Table 5: Pipeline COVID-19 vaccines, Taiwan, 2020-22
Table 6: Available COVID-19 IVD products, Taiwan, 2020-22
Table 7: Pipeline COVID-19 IVD products, Taiwan, 2020-22
Table 8: Medical devices market, major segments ($M), Taiwan, 2021
Table 9: Hospital supplies market, revenue ($M) and market share (%) of major companies, Taiwan, 2021
Table 10: Hospital supplies market, revenue ($M) and market share (%) of major companies, Taiwan, 2021
Table 11: Nephrology and urology devices market, revenue ($M) and market share (%) of major companies, Taiwan, 2021
Table 12: Cardiovascular devices market, revenue ($M) and market share (%) of major companies, Taiwan, 2021
Table 13: Diabetes care devices market, revenue ($M) and market share (%) of major companies, Taiwan, 2021
Table 14: Premium contribution ratios under NHI system, Taiwan, 2022
Table 15: Coinsurance for inpatient care, Taiwan, 2022
Table 16: Comparison of private health insurance types, Taiwan, 2022
Table 17: Registration fee structure for new drug application ($), Taiwan, 2022
Table 18: Schedule of patent fees, Taiwan, 2022
Table 19: Schedule of trademark fees, Taiwan, 2022
Table 20: Trade fairs, Taiwan, 2022

Figure 1: Pharmaceutical market (based on domestic production), revenue ($B), Taiwan, 2015-21
Figure 2: Medical devices market, revenue ($B), Taiwan, 2016-21
Figure 3: Healthcare start-ups in Taiwan, 2022
Figure 4: Country profile, Taiwan, 2022
Figure 5: Pharmaceutical market revenue ($B, based on domestic production), Taiwan, 2015-21
Figure 6: Pharmaceutical market (based on domestic production), revenue forecast ($B), Taiwan, 2022-26
Figure 7: Pharmaceutical exports ($M), Taiwan, 2011-21
Figure 8: Top export partners, Taiwan, 2021
Figure 9: Pharmaceutical imports ($B), Taiwan, 2011-21
Figure 10: Top import partners, Taiwan, 2021
Figure 11: Framework of the cross-departmental task force on counterfeit medicines in Taiwan, 2022
Figure 12: Major generic drug companies, Taiwan, 2022
Figure 13: Major domestic OTC manufacturers, Taiwan, 2022
Figure 14: COVID-19 (cumulative number of cases), Taiwan, 2020-22
Figure 15: COVID-19 (cumulative number of deaths), Taiwan, 2020-22
Figure 16: COVID-19 fiscal stimulus timeline, Taiwan, 2020-22
Figure 17: COVID-19 stringency index, Taiwan, 2020-22
Figure 18: COVID-19 containment and health index, Taiwan, 2020-22
Figure 19: Total number of vaccine doses administered by brand, Taiwan, 2021-22
Figure 20: COVID-19 vaccine dose administration (number of administered vaccine doses), Taiwan, 2021-22
Figure 21: COVID-19 clinical trials sponsors by count, Taiwan, 2020-22
Figure 22: COVID-19 clinical trials count by phase, Taiwan, 2020-22
Figure 23: COVID-19 clinical trials count by trial status, Taiwan, 2020-22
Figure 24: Medical devices market, revenue ($B), Taiwan, 2016-21
Figure 25: Medical devices market, revenue forecast ($B), Taiwan, 2022-27
Figure 26: Medical devices market, major segments (%), Taiwan, 2021
Figure 27: Hospital supplies market, revenue ($M), Taiwan, 2017-25
Figure 28: Hospital supplies market, market share of major players (%), Taiwan, 2021
Figure 29: Orthopedic devices market, revenue ($M), Taiwan, 2017-25
Figure 30: Orthopedic devices market, market share of major players (%), Taiwan, 2021
Figure 31: Nephrology and urology devices market, revenue ($M), Taiwan, 2017-25
Figure 32: Nephrology and urology devices market, market share of major players (%), Taiwan, 2021
Figure 33: Cardiovascular devices market, revenue ($M), Taiwan, 2017-25
Figure 34: Cardiovascular devices market, market share of major players (%), Taiwan, 2021
Figure 35: Diabetes care devices market, revenue ($M), Taiwan, 2017-25
Figure 36: Diabetes care devices market, market share of major players (%), Taiwan, 2021
Figure 37: Diagnostic market, revenue ($M), Taiwan, 2016-21
Figure 38: Diagnostic market, revenue ($M), Taiwan, 2022-27
Figure 39: Medical devices market, revenue ($B) of major companies, Taiwan, 2021
Figure 40: Deals value and deal count, pharmaceutical market, Taiwan, 2019-22
Figure 41: Deals value and deal count, quarterly, pharmaceutical market, Taiwan, 2019-22
Figure 42: Deals value and deal count, subtypes, pharmaceutical market, Taiwan, 2019-22
Figure 43: Top therapy areas by deal value ($M), pharmaceutical market, Taiwan, 2019-22
Figure 44: Top therapy areas by deal count, pharmaceutical market, Taiwan, 2019-22
Figure 45: M&A deals by quarter (by value and by number), pharmaceutical market, Taiwan, 2019-22
Figure 46: VC deals by quarter (by value and by number), pharmaceutical market, Taiwan, 2019-22
Figure 47: Deals value and deal count, medical devices market, Taiwan, 2019-22
Figure 48: Deals value and deal count, quarterly, medical devices market, Taiwan, 2019-22
Figure 49: Deals value and deal count, subtypes, medical devices market, Taiwan, 2019-22
Figure 50: Top equipment sectors by deal value ($M), medical devices market, Taiwan, 2019-22
Figure 51: Top equipment sectors by deal count, medical devices market, Taiwan, 2019-22
Figure 52: M&A deals by quarter (by value and by number), medical devices market, Taiwan, 2019-22
Figure 53: VC deals by quarter (by value and by number), medical devices market, Taiwan, 2019-22
Figure 54: Digital Government 2.0 Program (2021-25), objectives, Taiwan, 2021
Figure 55: Deals value ($M), Healthtech, Taiwan, 2019-22
Figure 56:Deal count (number of deals), Healthtech, Taiwan, 2019-22
Figure 57: Overview of healthcare system, Taiwan, 2022
Figure 58: HTA assessment for application of NHI new drug listing, Taiwan, 2022
Figure 59: OOP expenditure (% of current expenditure on health), Taiwan, 2013-20
Figure 60: Consumer price index in healthcare sector (Base Year 2016=100) , Taiwan, 2013-21
Figure 61: Organizational structure of TFDA, Taiwan, 2022
Figure 62: Organizational structure of center for drug evaluation, Taiwan, 2022
Figure 63: New drug approval process, regulatory landscape, Taiwan, 2022
Figure 64: Generics drug review process, Taiwan, 2022
Figure 65: Drug review process for NDA, Taiwan, 2022
Figure 66: Key elements, Medical Device Act, Taiwan, 2022
Figure 67: Total product life cycle management process, Taiwan, 2022
Figure 68: Regulatory requirement for medical devices, Taiwan, 2022
Figure 69: Marketing authorization procedure for medical devices, Taiwan, 2022
Figure 70: Clinical trial regulation process for an investigational new drug, Taiwan, 2022
Figure 71: Pharmaceutical clinical trials count by trial status, Taiwan, 2020-22
Figure 72: Pharmaceutical clinical trials count by therapy areas, Taiwan, 2020-22
Figure 73: Pharmaceutical clinical trials count by phase, Taiwan, 2020-22
Figure 74: Top five pharmaceutical clinical trials sponsors by count, Taiwan, 2020-22
Figure 75: Medical devices clinical trials count by trial status, Taiwan, 2020-22
Figure 76: Medical devices clinical trials count by therapeutic areas, Taiwan, 2020-22
Figure 77: Medical devices clinical trials count by indication, Taiwan, 2020-22
Figure 78: Top five medical devices clinical trials sponsors by count, Taiwan, 2020-22
Figure 79: Number of hospitals, Taiwan, 2011-21
Figure 80: Number of diagnostic equipment units (per 100,000 population), Taiwan, 2015-22
Figure 81: Number of clinics (per 1000 population), Taiwan, 2011-21
Figure 82: Hospitals (by Standard of Care), Contracted by NHIA, Taiwan, 2013-20
Figure 83: Hospital Beds (per 10,000 population), Taiwan, 2011-21
Figure 84: Number of Hospital Beds (by Specialty Care), Taiwan, 2020
Figure 85: Immunization coverage (%), Taiwan, 2020
Figure 86: Life expectancy at birth (years), Taiwan, 2013-21
Figure 87: CO2 emissions (tons per capita), Taiwan, 2011-21
Figure 88: Physicians (per 10,000 population), Taiwan, 2011-21
Figure 89: Nurses (per 10,000 population), Taiwan, 2011-21
Figure 90: Pharmacists (per 10,000 population), Taiwan, 2011-21
Figure 91: Dentists (per 10,000 population), Taiwan, 2011-21
Figure 92: Major causes of mortality (per 100,000 population), Taiwan, 2020
Figure 93: Major causes of male mortality (per 100,000 population), Taiwan, 2020
Figure 94: Major causes of female mortality (per 100,000 population), Taiwan, 2020
Figure 95: Healthcare expenditure as percentage of GDP (%), Taiwan, 2011-20
Figure 96: Public-private share (% of total health spending), Taiwan, 2011-20
Figure 97: Pharmaceutical spending (% of GDP), Taiwan, 2013-20
Figure 98: Current healthcare expenditure (per capita, $B), Taiwan, 2011-20
Figure 99: Share of national health expenditure (by financial resources), Taiwan, 2020